Hideho Okada

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc EphA2 as a glioma-associated antigen: a novel target for glioma vaccines
    Manabu Hatano
    Department of Neurological Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Neoplasia 7:717-22. 2005
  2. pmc Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Transl Med 5:68. 2007
  3. doi request reprint Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10
    Mitsugu Fujita
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer Res 69:1587-95. 2009
  4. pmc Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners
    Xinmei Zhu
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Immunol Immunother 59:1401-9. 2010
  5. pmc Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011
    Ivan Martinez Forero
    Centro de Investigación Médica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain
    J Transl Med 10:108. 2012
  6. pmc Integration of epidemiology, immunobiology, and translational research for brain tumors
    Hideho Okada
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Ann N Y Acad Sci 1284:17-23. 2013
  7. pmc Type17 T-cells in central nervous system autoimmunity and tumors
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Immunol 32:802-8. 2012
  8. pmc Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Transl Med 5:67. 2007
  9. pmc Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in
    Hideho Okada
    G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
    J Clin Oncol 29:330-6. 2011
  10. pmc Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Neurooncol 88:245-50. 2008

Research Grants

Collaborators

Detail Information

Publications59

  1. pmc EphA2 as a glioma-associated antigen: a novel target for glioma vaccines
    Manabu Hatano
    Department of Neurological Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Neoplasia 7:717-22. 2005
    ..Taken together, these data suggest that EphA2883-891 may be an attractive antigen epitope for molecularly targeted glioma vaccines...
  2. pmc Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Transl Med 5:68. 2007
    ..In this report, we characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with anaplastic astrocytoma (AA) for over 12 years without recurrence...
  3. doi request reprint Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10
    Mitsugu Fujita
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer Res 69:1587-95. 2009
    ..Collectively, these findings show the anti-CNS glioma effects of DC1-based therapy and a novel role of CXCL10 in the immunologic and therapeutic activity of DC-based cancer vaccines...
  4. pmc Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners
    Xinmei Zhu
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Immunol Immunother 59:1401-9. 2010
    ..Our data point to critical roles of the host-IFN-alpha and IFN-gamma pathways in the modulation of CNS glioma microenvironment, and the therapeutic effectiveness of poly-ICLC-assisted glioma vaccines...
  5. pmc Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011
    Ivan Martinez Forero
    Centro de Investigación Médica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain
    J Transl Med 10:108. 2012
    ..The general perception is that the road ahead of us is full of combination clinical trials which hopefully will bring clinical benefit to our cancer patients at a fast pace...
  6. pmc Integration of epidemiology, immunobiology, and translational research for brain tumors
    Hideho Okada
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Ann N Y Acad Sci 1284:17-23. 2013
    ..Future research will hopefully better integrate epidemiological, immunobiological, and translational techniques to develop novel, preventive approaches for malignant gliomas...
  7. pmc Type17 T-cells in central nervous system autoimmunity and tumors
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Immunol 32:802-8. 2012
    ..The insight gained from these findings may lead to the development of novel therapeutic and prophylactic strategies for CNS autoimmunity and tumors...
  8. pmc Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Transl Med 5:67. 2007
    ..The prognosis for malignant gliomas remains dismal. We addressed the safety, feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and interleukin (IL)-4 gene transfected fibroblasts...
  9. pmc Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in
    Hideho Okada
    G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
    J Clin Oncol 29:330-6. 2011
    ..GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100...
  10. pmc Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Neurooncol 88:245-50. 2008
    ..These results suggest that EphA2, IL-13Ralpha2 and Survivin are suitable targets for developing vaccine strategies for pediatric glioma...
  11. doi request reprint Brain tumor immunotherapy with type-1 polarizing strategies
    Hideho Okada
    University of Pittsburgh School of Medicine, Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Ann N Y Acad Sci 1174:18-23. 2009
    ..Based on these data, we have implemented a phase I/II vaccination study using type 1 polarizing DCs loaded with GAA peptides in combination with poly-ICLC in patients with recurrent malignant glioma...
  12. pmc Immunotherapeutic approaches for glioma
    Hideho Okada
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Crit Rev Immunol 29:1-42. 2009
    ..Finally, we discuss how each of these promising strategies can be combined to achieve clinical benefit for patients with gliomas...
  13. ncbi request reprint Cytokine gene therapy for malignant glioma
    Hideho Okada
    University of Pittsburgh Medical Center Cancer Institute, Department of Neurological Surgery, Brain Tumor Program, G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
    Expert Opin Biol Ther 4:1609-20. 2004
    ..Successful immunogene therapy for brain tumours requires detailed understanding of cytokine functions and the use of them at the appropriate stages/sites of the immunological milieu...
  14. pmc MicroRNAs in immune regulation--opportunities for cancer immunotherapy
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Int J Biochem Cell Biol 42:1256-61. 2010
    ..We have also demonstrated that the ability of tumors to serve as targets for cytolytic effectors is regulated by miR-222 and miR-339...
  15. ncbi request reprint Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways
    Naruo Kuwashima
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, PA 15213, USA
    J Immunol 175:2730-40. 2005
    ....
  16. pmc Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 106:10746-51. 2009
    ..This study suggests development of novel miR-targeted therapy to promote cytolysis of tumor cells...
  17. ncbi request reprint Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma
    Mitsugu Fujita
    Department of Neurological Surgery and Brain Tumor Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    J Immunol 180:2089-98. 2008
    ....
  18. pmc Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 15:6551-9. 2009
    ..We hypothesized that inhibition of TGF-beta would improve the efficacy of vaccines targeting glioma-associated antigen (GAA)-derived CTL epitopes by reversal of immunosuppression...
  19. pmc Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models
    Xinmei Zhu
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Transl Med 5:10. 2007
    ....
  20. pmc IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Immunother 32:793-802. 2009
    ..These data suggest that treatment strategies capable of sustaining/enhancing VLA-4/VLA-6 expression on Th1 effector cells may yield improved clinical efficacy in the cancer setting...
  21. ncbi request reprint Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses
    Junichi Eguchi
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, USA
    Cancer Res 66:5883-91. 2006
    ..These findings indicate highly immunogenic IL-13Ralpha2 peptide analogues may be useful for the development of vaccines capable of effectively expanding IL-13Ralpha2-specific, tumor-reactive CTLs in glioma patients...
  22. pmc IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Eur J Immunol 38:2865-73. 2008
    ..These results suggest a novel suppressive mechanism for IL-4 that limits Tc1 efficacy via preventing their recruitment into tumors...
  23. ncbi request reprint IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity
    Junichi Eguchi
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, PA 15213, USA
    J Immunol 174:7194-201. 2005
    ..These results suggest that vaccines consisting of tumor cells engineered to produce the type 2 cytokine, IL-4, critically depend on type 1 immunity for their observed therapeutic efficacy...
  24. pmc Premetastatic soil and prevention of breast cancer brain metastasis
    Yan Liu
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Neuro Oncol 15:891-903. 2013
    ..As therapies for systemic cancer improve and patients survive longer, the risk for brain metastases increases. We evaluated whether immune mechanisms are involved in the development of brain metastasis...
  25. ncbi request reprint Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10
    Fumihiko Nishimura
    Department of Neurological Surgery, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Cancer Res 66:4478-87. 2006
    ..These data suggest that Tc1-based adoptive transfer therapy may represent an effective modality for CNS tumors, particularly when combined with strategies that promote a type 1 polarized tumor microenvironment...
  26. pmc Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans
    Mitsugu Fujita
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 16:3409-19. 2010
    ..We hypothesized that the type 1 IFNs would play a pivotal role in antiglioma immunosurveillance through promotion of type 1 adaptive immunity and suppression of immunoregulatory cells...
  27. ncbi request reprint The characterization of tumor apoptosis after experimental radiosurgery
    Timothy F Witham
    Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
    Stereotact Funct Neurosurg 83:17-24. 2005
    ..The time course of this radiobiologic phenomenon begins at approximately 6 h following radiosurgery, continues up to 48 h, and begins to decline by 72 h...
  28. pmc GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α
    Gary Kohanbash
    Authors Affiliations Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health Brain Tumor Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center Departments of Neurological Surgery, Surgery, and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania and Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota
    Cancer Res 73:6413-23. 2013
    ..Together, our findings establish a GM-CSF-induced mechanism of immunosuppression in the glioma microenvironment via upregulation of IL-4Rα on MDSCs...
  29. ncbi request reprint Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors
    Hidemitsu Sato
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 1863, USA
    Cancer Gene Ther 12:757-68. 2005
    ..These data indicate that EGFR-MSCs may serve as attractive vehicles for infiltrating brain malignancies such as malignant gliomas...
  30. pmc miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy
    Kotaro Sasaki
    Department of Immunology, University of Pittsburgh School of Medicine, PA 15213, USA
    J Transl Med 8:17. 2010
    ..We identified miRs differentially regulated between type-1 and type-2 T cells, and determined how the expression of such miRs is regulated...
  31. ncbi request reprint Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, PA, USA
    J Neurooncol 64:13-20. 2003
    ..While it is premature to assess effectiveness of the vaccine, this initial patient's course suggested a transient response to the vaccine, and he survived 10 months after treatment...
  32. ncbi request reprint Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines
    Hideho Okada
    Departments of Neurological Surgery, University of Pittsburgh School of Medicine, PA 15213, USA
    Cancer Res 64:5830-8. 2004
    ..On the basis of these results, we believe that local expression of IFN-alpha by DCs within the intracranial tumor site may enhance the clinical efficacy of peripheral vaccine approaches for brain tumors...
  33. pmc Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 181:104-8. 2008
    ..These results suggest that Stat6-signaling is necessary and sufficient to restrict CD8+ T cell expression of VLA-4 (by IL-4), thereby serving as a regulator for CD8+ T cell infiltration into tumors...
  34. ncbi request reprint Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Res 67:6451-8. 2007
    ....
  35. ncbi request reprint Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy
    Aklile Berhanu
    Department of Immunology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Immunol 178:3400-8. 2007
    ..Importantly, in vivo depletion of CD4+ T cells resulted in the ability of previously ineffective, rFL plus rGM-CSF therapy-induced CD8+ T cells to now mediate tumor regression...
  36. pmc Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity
    Yutaro Nakamura
    Department of Surgery, University of Pittsburgh, Eye and Ear Institute, PA 15213 1863, USA
    Cancer Res 67:10012-8. 2007
    ....
  37. pmc LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma
    Jacky T Yeung
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 19:1816-26. 2013
    ..In this study, we examined the prevalence of these LOH events and their relations with overall survival in GBM...
  38. ncbi request reprint Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo
    Timothy F Witham
    Brain Tumor Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 1863, USA
    J Neurooncol 64:63-9. 2003
    ..Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFbeta sr in vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model...
  39. ncbi request reprint 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model
    Timothy F Witham
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pennsylvania, USA
    Neurosurgery 50:1327-34; discussion 1334-5. 2002
    ....
  40. ncbi request reprint Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain
    Fumiyoshi Okano
    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2851-5. 2002
    ..Interleukin 13 receptor alpha2-chain (IL-13Ralpha2) has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme. Here we report the identification of a CTL epitope derived from the IL-13Ralpha2...
  41. pmc Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
    Xinmei Zhu
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Neurooncol 104:83-92. 2011
    ..0359). These observations provide support for development of mAb-based CCL2 blockade strategies in combination with the current standard TMZ-based chemotherapy for treatment of malignant gliomas...
  42. pmc COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells
    Mitsugu Fujita
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer Res 71:2664-74. 2011
    ..Taken together, our findings show that the COX-2 pathway promotes gliomagenesis by directly supporting systemic development of MDSCs and their accumulation in the TME, where they limit CTL infiltration...
  43. pmc Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, United States
    Semin Immunol 22:173-82. 2010
    ..These developments allow for selective induction of tumor-specific T cells with desirable effector functions and tumor-relevant homing properties and to direct the desirable types of immune cells to tumors...
  44. pmc Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Immunol Res 50:235-47. 2011
    ....
  45. ncbi request reprint [Immunotherapy for brain tumor: don't get "Lost in Translation"]
    Hideho Okada
    Department of Neurosurgery and Surgery, University of Pittsburgh Medical Center Cancer Institute, PA 15213 1863, USA
    No Shinkei Geka 33:433-42. 2005
  46. pmc Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy
    Jacky T Yeung
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Neurooncol 111:103-11. 2013
    ..Pediatric and adult ependymomas frequently express EphA2, IL-13Rα2, and Survivin. This provides the basis for the utilization of an established multiple peptide vaccine for ependymoma in a clinical trial setting...
  47. pmc Expression of antigen processing and presenting molecules in brain metastasis of breast cancer
    Yan Liu
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Immunol Immunother 61:789-801. 2012
    ..Taken together, our data suggest that patients with low or defective TAP1 or calnexin in primary breast cancers may be at higher risks for developing brain metastasis due to the defects in T cell-based immunosurveillance...
  48. doi request reprint Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development
    Gary Kohanbash
    Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
    Immunol Invest 41:658-79. 2012
    ..The insight gained from these findings may lead to the development of novel immunotherapeutic strategies for gliomas...
  49. pmc MicroRNAs and STAT interplay
    Gary Kohanbash
    Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
    Semin Cancer Biol 22:70-5. 2012
    ..As we learn more about miR pathways, we gain the opportunity to manipulate them in cancer cells to slow down growth or increase their susceptibility anti-tumor immunity...
  50. ncbi request reprint Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity
    Tomohide Tatsumi
    Department of Surgery, University of Pittsburgh School of Medicine, The Hillman Cancer Center, 5117 Center Avenue, Pittsburgh, PA 15213, USA
    Cancer Res 63:6378-86. 2003
    ....
  51. ncbi request reprint Gene therapy and biologic therapy with interleukin-4
    Hideho Okada
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 1863, USA
    Curr Gene Ther 2:437-50. 2002
    ..This review discusses biological properties and therapeutic applications of IL-4, particularly when it is delivered as a transgene in the settings of gene therapy...
  52. ncbi request reprint Biologic therapy for brain cancers--based on cellular and immunobiology
    Hideho Okada
    Department of Neurosurgery and Surgery, University of Pittsburgh Medical Center Cancer Institute, G12 aResearch Pavilion at the Hillman Cancer Center, Pittsburgh, PA, 15213 1863, USA
    Yonsei Med J 45:68-70. 2004
    ....
  53. doi request reprint Ependymomas: development of immunotherapeutic strategies
    Ian F Pollack
    Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Expert Rev Neurother 13:1089-98. 2013
    ....
  54. pmc Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice
    Xi Zhao
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 188:1782-8. 2012
    ..This suggests that the vaccine-induced anti-TBVA T cell repertoire can mediate the clinically preferred outcomes of either effectively eradicating tumors or policing a state of (occult) tumor dormancy...
  55. pmc Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice
    Huihui Ma
    Department of Medicine, Division of Hematology Oncology, Hematologic Malignancies Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 1863, USA
    J Clin Invest 121:2554-69. 2011
    ..These observations demonstrate that Stat1 is a regulator of Tregs and that targeting Stat1 in CD4+ T cells may facilitate in vitro and in vivo expansion of Tregs for therapeutic use...
  56. ncbi request reprint Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas
    Tianbing Yang
    Brain Tumor Center, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Cancer Res 62:2583-91. 2002
    ..These data indicate that HA expressed by gliomas may contribute to their immunosuppressive effects by promoting apoptosis among professional antigen-presenting cells such as DCs via iNOS induction after CD44-HA interactions...
  57. ncbi request reprint Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells
    Norimoto Nakahara
    Department of Bio Medicine, Nagoya University School of Medicine, Nagoya, Japan
    Cancer Gene Ther 10:549-58. 2003
    ..Suppression of the tumor growth by this combinational therapy was superior to treatment with DC or IFN-beta gene solely. This combination may constitute a new therapeutic strategy to induce potent antiglioma immune responses...
  58. ncbi request reprint Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics
    Jian Gang Zhang
    Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long Beach, CA 90822, USA
    Clin Cancer Res 13:566-75. 2007
    ....
  59. ncbi request reprint Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis
    Tobey J Macdonald
    Center for Cancer and Immunology Research, Children s Research Institute, Department of Hematology Oncology, Children s National Medical Center, Washington, DC, USA
    Methods Mol Biol 377:203-22. 2007
    ..Further investigation is needed to evaluate the role of APOD, as well as the other genes identified, in malignant astrocytoma development...

Research Grants5

  1. Giloma Vaccines in Combination with Poly-ICLC
    Hideho Okada; Fiscal Year: 2009
    ....
  2. Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas
    Hideho Okada; Fiscal Year: 2007
    ..Information from this pilot study will establish a basis to design subsequent trials with patient populations in which more significant clinical benefit might be realized. ..
  3. Giloma Vaccines in Combination with Poly-ICLC
    Hideho Okada; Fiscal Year: 2007
    ....